Teva Throws Wyeth Year-End Curve Ball With Launch Of Generic Protonix
Executive Summary
Teva's launch of a generic version of Wyeth's proton pump inhibitorProtonix (pantoprazole) means that Wyeth must quickly decide how much faith to place in its patent as it negotiates a potential settlement
You may also be interested in...
Teva’s At-Risk Launch Of Pulmicort Generics May Cost It Exclusivity
Teva's exclusivity clock may already be ticking following the short-lived launch of a generic version of AstraZeneca's Pulmicort. Generic sales for the product are now suspended by court order with a hearing on the preliminary injunction scheduled for Nov. 25
Teva’s At-Risk Launch Of Pulmicort Generics May Cost It Exclusivity
Teva's exclusivity clock may already be ticking following the short-lived launch of a generic version of AstraZeneca's Pulmicort. Generic sales for the product are now suspended by court order with a hearing on the preliminary injunction scheduled for Nov. 25
Teva R&D Spending Target Raised To 7.5% Of Sales
Teva Pharmaceuticals will boost research and development spending this year toward a new goal of 7.5 percent of sales, company executives announced during the firm's fourth quarter earnings call Feb. 12